Skip to main content
Premium Trial:

Request an Annual Quote

Anthony Mattacchione

Bruker has named Anthony Mattacchione its new CFO, effective immediately. He has served as the firm's interim CFO since June 2015 and previously was Bruker's SVP of finance and accounting. Before joining Bruker, Mattacchione was CFO of EMD Millipore, a subsidiary of Germany's Merck KGaA. From 2006 to 2010, he served as controller and chief accounting officer for Millipore.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.